Skip to main content
Clinical Trials/NCT05961852
NCT05961852
Completed
Phase 1

COmbiNing Cutting and Drug-Eluting Balloon for Resistant Arteriovenous Fistula sTenOsis (CONCERTO)

Singapore General Hospital1 site in 1 country19 target enrollmentAugust 15, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Arteriovenous Fistula Stenosis
Sponsor
Singapore General Hospital
Enrollment
19
Locations
1
Primary Endpoint
Target lesion primary patency
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

To evaluate the preliminary efficacy of combination of cutting and drug-coated balloon for the treatment of resistant AVF stenosis.

Detailed Description

This is a single arm pilot study recruiting 19 participants with resistant AVF stenosis (defined as having \> 30% residual stenosis after optimal balloon angioplasty) to receive cutting and drug-coated balloon. The outcome measure is target lesion primary patency at 6 months. Outcome will be clinically driven.

Registry
clinicaltrials.gov
Start Date
August 15, 2018
End Date
June 30, 2019
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Failing mature upper limb AVF
  • Resistant stenosis (\>30% residual stenosis) after optimal conventional balloon angioplasty (appropriately sized balloon, inflated up to rated burst pressure, at least twice for at least a minute per inflation)
  • Patient is \>= 21 years of age
  • Ability to provide informed consent

Exclusion Criteria

  • Thrombosed AVF
  • Target lesion has a sharp angle (\> 45 degrees)
  • Lesions requiring cutting balloon size \> 7 mm
  • Coagulopathy or thrombocytopaenia that cannot be adequately managed for the procedure
  • Contraindication to dual antiplatelet therapy
  • Severe allergy to contrast media that cannot be adequately managed for the procedure
  • Breast-feeding and/or pregnant females
  • Male patients who are planning to father children during the trial period
  • Unable to comply with follow up protocol (for instance, limited life expectancy)

Outcomes

Primary Outcomes

Target lesion primary patency

Time Frame: 6 months after index procedure

Time from index treatment to repeat treatment of target lesion or thrombosis of circuit.

Study Sites (1)

Loading locations...

Similar Trials